The convergence of medicine, technology and artificial intelligence is often touted as one of the sharemarket’s next great investment trends, with the “medtech” sector producing several eye-watering winners for investors over the past decade.

On the S&P/ASX 200, shares in medtech business Pro Medicus are 100 times higher since 2014 and hit a record high of $111.88 on February 12 at an $11.6 billion valuation, thanks to its success selling AI-assisted medical imaging software in the US.